Bifogade filer
Kurs & Likviditet
Beskrivning
Land | Danmark |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Hørsholm, Denmark, August 10, 2022 - ExpreS2ion Biotech Holding AB ("ExpreS2ion") today announces that 136,422 warrants held by employees under the 2019 Warrant Program ("TO2") have been fully exercised, providing ExpreS2ion SEK 656,190. The exercise has increased the number of shares by 136,422 from 37,162,106 to 37,298,528.
At an Extra General Meeting in ExpreS[2]ion held on May 23, 2019, it was resolved to issue warrants as part of an incentive program for employees ("the 2019 Warrant Program", or "TO2"). The program comprised a total of 680,100 warrants, where one (1) warrant entitled to subscription of one (1) share in the Company. 612,084 were subscribed for and allocated to the employees. The warrants stipulated a subscription price of SEK 4.81 per share. The TO2 exercise period is in three months from June 1 through August 31 and is carried out in three tranches during the respective months. The first tranche was announced on July 11 (https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces-exercise-of-2019-warrant-program,c3599701). The 136,422 warrants cover the second of the three tranches.
Number of shares, share capital and dilution
The new shares in the second tranche have now been registered by the Swedish Companies Registration Office (Sw. Bolagsverket). The number of shares in ExpreS[2]ion has increased by 136,422, from 37,162,106 to 37,298,528 shares. The total share capital amounts to SEK 4,144,280.90. The dilution effect for the company's existing shareholders amounted to approximately 0.37 percent.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se